Idiopathic pulmonary fibrosis: Prognostic value of changes in physiology and six-minute-walk test

American Journal of Respiratory and Critical Care Medicine

Volumn 174, Issue 7, 2006, Pages 803-809

  Flaherty, Kevin R ^a   Andrei, Adin Cristian ^b   Murray, Susan ^b   Fraley, Chris ^b   Colby, Thomas V ^b   Travis, William D ^b   Lama, Vibha ^b   Kazerooni, Ella A ^b   Gross, Barry H ^b   Toews, Galen B ^b   Martinez, Fernando J ^b  

^a UNIVERSITY OF MICHIGAN HEALTH SYSTEM   (United States)

^b NONE

Author keywords

Idiopathic pulmonary fibrosis; Prognosis; Pulmonary function; Six minute walk test; Survival

Indexed keywords

CARBON MONOXIDE;

ADULT; AGED; ARTICLE; CONTROLLED STUDY; FEMALE; HUMAN; IDIOPATHIC DISEASE; LUNG DIFFUSION CAPACITY; LUNG FIBROSIS; MAJOR CLINICAL STUDY; MALE; MORTALITY; MULTIVARIATE ANALYSIS; PRIORITY JOURNAL; PROGNOSIS; RELIABILITY; SURVIVAL; VITAL CAPACITY; WALKING;

AGED; CARBON MONOXIDE; EXERCISE TEST; FEMALE; HUMANS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; PROGNOSIS; PULMONARY DIFFUSING CAPACITY; PULMONARY FIBROSIS; RETROSPECTIVE STUDIES; RISK FACTORS; SURVIVAL ANALYSIS; VITAL CAPACITY;

EID: 33749434364     PISSN: 1073449X     EISSN: 1073449X     Source Type: Journal    
DOI: 10.1164/rccm.200604-488OC     Document Type: Article

References (29)

1. King T Jr, Tooze J, Schwarz M, Brown K, Cherniack R. Predicting survival in idiopathic pulmonary fibrosis: Scoring system and survival model. Am J Respir Crit Care Med 2001;164:1171-1181.
2. King T Jr, Schwarz M, Brown K, Tooze J, Colby T, Waldron J Jr, Flint A, Thurlbeck W, Cherniack R. Idiopathic pulmonary fibrosis: relationship between histopathologic features and mortality. Am J Respir Crit Care Med 2001;164:1025-1032.
3. Flaherty K, Toews G, Travis W, Colby T, Kazerooni E, Gross B, Jain A, Strawderman R III, Paine R III, Flint A, et al. Clinical significance of histological classification of idiopathic interstitial pneumonia. Eur Respir J 2002;19:275-283.
4. Lama V, Flaherty K, Toews G, Colby T, Travis W, Long Q, Murray S, Kazerooni E, Gross B, Lynch J III, et al. Prognostic value of desaturation during a 6-minute walk test in idiopathic interstitial pneumonia. Am J Respir Crit Care Med 2003;168:1084-1090.
5. Mogulkoc N, Brutsche MH, Bishop PW, Greaves SM, Horrocks AW, Egan JJ. Pulmonary function in idiopathic pulmonary fibrosis and referral for lung transplantation. Am J Respir Crit Care Med 2001;164:103-108.
6. Hallstrand TS, Boitano LJ, Johnson WC, Spada CA, Hayes JG, Raghu G. The timed walk test as a measure of severity and survival in idiopathic pulmonary fibrosis. Eur Respir J 2005;25:96-103.
7. Eaton T, Young P, Milne D, Wells AU. Six-minute walk, maximal exercise tests: reproducibility in fibrotic interstitial pneumonia. Am J Respir Crit Care Med 2005;171:1150-1157.
8. Jegal Y, Kim DS, Shim TS, Lim CM, Do Lee S, Koh Y, Kim WS, Kim WD, Lee JS, Travis WD, et al. Physiology is a stronger predictor of survival than pathology in fibrotic interstitial pneumonia. Am J Respir Crit Care Med 2005;171:639-644.
9. Latsi PI, du Bois RM, Nicholson AG, Colby TV, Bisirtzoglou D, Nikolakopoulou A, Veeraraghavan S, Hansell DM, Wells AU. Fibrotic idiopathic interstitial pneumonia: the prognostic value of longitudinal functional trends. Am J Respir Crit Care Med 2003;168:531-537.
10. Collard H, King T, Bartelson B, Vourlekis J, Schwarz M, Brown K. Changes in clinical and physiologic variables predict survival in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 2003;168:538-542.
11. Flaherty K, Mumford J, Murray S, Kazerooni E, Gross B, Colby T, Travis W, Flint A, Toews G, Lynch J, et al. Prognostic implications of physiologic and radiographic changes in idiopathic interstitial pneumonia. Am J Respir Crit Care Med 2003;168:543-548.
12. Agusti AG, Roca J, Rodriguez-Roisin R, Xaubet A, Agusti-Vidal A. Different patterns of gas exchange response to exercise in asbestosis and idiopathic pulmonary fibrosis. Eur Respir J 1988;1:510-516.
13. American Thoracic Society. Idiopathic pulmonary fibrosis: diagnosis and treatment. International consensus statement. Am J Respir Crit Care Med 2000;161:646-664.
14. Jernudd-Wilhelmsson Y, Hornblad Y, Hedenstierna G. Ventilation-perfusion relationships in interstitial lung disease. Eur J Respir Dis 1986;68:39-49.
15. Wagner PD. Ventilation-perfusion matching during exercise. Chest 1992;101:192S-198S.
16. Hansen J, Wasserman K. Pathophysiology of activity limitation in patients with interstitial lung disease. Chest 1996;109:1566-1576.
17. Hunninghake G, Lynch D, Galvin J, Muller N, Schwartz D, King T Jr, Lynch JIII, Hegele R, Waldron J Jr, Colby T, Hogg J. Radiologic findings are strongly associated with a pathologic diagnosis of usual interstitial pneumonia. Chest 2003;124:1215-1223.
18. Flaherty K, Thwaite E, Kazerooni E, Gross B, Toews G, Colby T, Travis W, Mumford J, Murray S, Flint A, et al. Radiological versus histological diagnosis in UIP and NSIP: survival implications. Thorax 2003;58:143-148.
19. Flaherty K, Travis W, Colby T, Toews G, Kazerooni E, Gross B, Jain A, Strawderman R III, Flint A, Lynch J III, et al. Histologic variability in usual and nonspecific interstitial pneumonias. Am J Respir Crit Care Med 2001;164:1722-1727.
20. Flaherty KR, King TE Jr, Raghu G, Lynch JP III, Colby TV, Travis WD, Gross BH, Kazerooni EA, Toews GB, Long Q, et al. Idiopathic interstitial pneumonia: what is the effect of a multidisciplinary approach to diagnosis? Am J Respir Crit Care Med 2004;170:904-910.
21. Fraley C, Martinez F, Lama V, Colby T, Travis W, Toews G, Flint A, Chang A, Flaherty K. Distance walking during a six minute walk test (6MWT) relative to the quantity of desaturation predicts mortality in patients with idiopathic pulmonary fibrosis (IPF). Proc Am Thorac Soc 2005;2:A316.
22. Gay S, Kazerooni E, Toews G, Lynch J III, Gross B, Cascade P, Spizarny D, Flint A, Schork M, Whyte R, et al. Idiopathic pulmonary fibrosis: predicting response to therapy and survival. Am J Respir Crit Care Med 1998;157:1063-1072.
23. Kawut SM, O'Shea MK, Bartels MN, Wilt JS, Sonett JR, Arcasoy SM. Exercise testing determines survival in patients with diffuse parenchymal lung disease evaluated for lung transplantation. Respir Med 2005;99:1431-1439.
24. Azuma A, Nukiwa T, Tsuboi E, Suga M, Abe S, Nakata K, Taguchi Y, Nagai S, Itoh H, Ohi M, et al. Double-blind, placebo-controlled trial of pirfenidone in patients with idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 2005;171:1040-1047.
25. Frost AE, Langleben D, Oudiz R, Hill N, Horn E, McLaughlin V, Robbins IM, Shapiro S, Tapson VF, Zwicke D, et al. The 6-min walk test (6MW) as an efficacy endpoint in pulmonary arterial hypertension clinical trials: demonstration of a ceiling effect. Vascul Pharmacol 2005;43:36-39.
26. Bosentan studies in pulmonary fibrosis show no effect on primary exercise improvement endpoint: secondary endpoints related to death or disease worsening provide strong rationale for Phase III mortality/morbidity study in Idiopathic Pulmonary Fibrosis (IPF).Available from: www.actelion.com/uninet/www/www_main_p. nsf/Content/me+28 Nov+2005 (accessed April 4, 2006).
27. King TE Jr, Safrin S, Starko KM, Brown KK, Noble PW, Raghu G, Schwartz DA. Analyses of efficacy end points in a controlled trial of interferon-gamma1b for idiopathic pulmonary fibrosis. Chest 2005;127:171-177.
28. Martinez FJ, Safrin S, Weycker D, Starko KM, Bradford WZ, King TE Jr, Flaherty KR, Schwartz DA, Noble PW, Raghu G, et al. The clinical course of patients with idiopathic pulmonary fibrosis. Ann Intern Med 2005;142:963-967.
29. Egan JJ, Martinez FJ, Wells AU, Williams T. Lung function estimates in idiopathic pulmonary fibrosis: the potential for a simple classification. Thorax 2005;60:270-273.